Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Mr Strachan on X..
View:
Post by alleyesonme on Jan 08, 2024 3:04pm

Mr Strachan on X..

S1i...wow.."hurry up FDA" agree this says it all....global pharma partner expecting FDA approval...or clinical trial approval...explosive comments...he probably shouldn't of said anything..nevertheless, patiently wait we will...meanwhile dronabinol generic ready for Germany..ANVISA approval/shipments expected this quarter, possibly a new pharmaceutical..meanwhile DEA rescheduling announcement imminent..Canadian cannabis review, final report due for House of Commons/senate by March.....3m additional annualized  savings commenced Q3....Y/E,Q4 out March including sales without shelter royalties, higher margin German flower sales, and new high demand vapes, distillates and flower for the tighter Australian market to name a few...dang.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities